Skip to main content
. 2017 Oct 16;7:12813. doi: 10.1038/s41598-017-12648-1

Figure 3.

Figure 3

Effects of PD98059, a pERK1/2 inhibitor, on LPS-mediated COX-2 expression in AGS cells. (a) Cells were treated with and without 10 ng/mL LPS for 15, 30, and 60 min. Cell lysates were harvested for a pERK1/2 expression analysis. To further determine the effect of PD98059 on LPS-medicated COX-2, cells were transiently transfected with 0.5 μg of (b) a COX-2 promoter reporter construct (pXC918) and (c) 3X NF-κB reporter construct for 24 h. Cells were incubated with 10 μM PD98059 for 30 min, and stimulated with 10 ng/mL LPS for 2 h. Promoter activity was measured with a luciferase assay. Statistical significance (**p < 0.01) of the difference between control and LPS-treated cells was determined by Student’s t-test.